Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RANI stock hub

Rani Therapeutics Holdings, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RANIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

96.4M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RANI

In the news

Latest news · RANI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-182

P25 -105.6P50 -46.5P75 -3.1

ROIC-60.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RANI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

205

Groups with data

Currency

USD

Showing 205 of 205 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001856725
Company name	Rani Therapeutics Holdings, Inc.
Country	United States
Country code	US
Cusip	753018100
Employees	71
Employees Change	-35%
Employees Change Percent	-33.02
Enterprise value	$51M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-07-30
Isin	US7530181004
Last refreshed	2026-05-10
Market cap	$96.4M
Market cap category	Micro-Cap
Price	$0.97
Price currency	USD
Rev Per Employee	23,000x
Sector	Healthcare
Sic	2834
Symbol	RANI
Website	https://www.ranitherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-30.79%
EV Sales Forward	24.99x
EV/Sales	31.22x
FCF yield	-19.51%
P/B ratio	2.86x
P/S ratio	59.01x
PS Forward	47.24x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$1.6M
Gross Profit Growth	58.85%
Gross Profit Growth Q	42.12%
Gross Profit Growth5 Y	28.73%
Net Income	$-29.7M
Net Income Growth Years	2%
Pretax Margin	-2,507.65%
Profit Per Employee	$-417,930
ROA	-50.27
Roa5y	-46.29
ROCE	-83.37
ROE	-182
Roe5y	-165.9
ROIC	-60.59

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	15.23%
Cagr3y	-41.03%
EPS Growth Quarters	4
EPS Growth Years	2
Revenue Growth	58.85x
Revenue Growth Q	42.12x
Revenue Growth Quarters	1x
Revenue Growth Years	1x
Revenue Growth5 Y	28.73x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$58.6M
Cash	$49.7M
Current Assets	$53.3M
Current Liabilities	$12.7M
Debt	$4.3M
Debt Equity	$0.1
Equity	$41.5M
Interest Coverage	-13.25
Liabilities	$17.1M
Long Term Assets	$5.3M
Long Term Liabilities	$4.4M
Net Cash	$45.4M
Net Cash By Market Cap	$47.1
Net Debt Equity	$-1.09
Tangible Book Value	$33M
Tangible Book Value Per Share	$0.34
WACC	10.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.21
Net Working Capital	$-7.5M
Quick ratio	4.08
Working Capital	$40.7M
Working Capital Turnover	$0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-132.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	15.22%
200-day SMA	1.12
3Y total return	-79.5%
50-day SMA	1.03
50-day SMA vs 200-day SMA	50under200
All Time High	36.27
All Time High Change	-97.34%
All Time High Date	2021-11-15
All Time Low	0.39
All Time Low Change	149.48%
All Time Low Date	2025-07-15
ATR	0.08
Beta	0.76
Beta1y	3.96
Beta2y	2.39
Ch YTD	-28.48
High	0.98
High52	3.87
High52 Date	2025-10-22
High52ch	-75.05%
Low	0.95
Low52	0.39
Low52 Date	2025-07-15
Low52ch	149.48%
Ma50ch	-6.44%
Premarket Change Percent	2.95
Premarket Price	$0.96
Premarket Volume	16,170
Price vs 200-day SMA	-13.56%
RSI	52.49
RSI Monthly	42.93
RSI Weekly	43.3
Sharpe ratio	0.74x
Sortino ratio	2.67
Total Return	-132.26%
Tr YTD	-28.48
Tr1m	18.09%
Tr1w	2.71%
Tr3m	-20.86%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$4
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.05
Earnings Revenue Estimate	500,000x
Earnings Revenue Estimate Growth	190.7x
Operating Income	$-38.3M
Operating margin	-2,346
Price target	$7.5
Price Target Change	$677
Price Target Change Top	$314

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	64,412,896%
Float Percent	64.53%
Net Borrowing	-20,722,000
Shares Insiders	3%
Shares Institutions	19.99%
Shares Out	99,812,515
Shares Qo Q	42.4%
Shares Yo Y	132.26%
Short Float	14.71%
Short Ratio	6.4
Short Shares	9.49

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-30.6M
Average Volume	707,131.3x
Bv Per Share	0.34
CAPEX	$-88,000
Ch1m	18.09
Ch1w	2.71
Ch1y	15.22
Ch3m	-20.86
Ch3y	-79.5
Ch6m	-52.2
Change	3.71%
Change From Open	-0.46
Close	0.93
Days Gap	4.19
Depreciation Amortization	900,000
Dollar Volume	388,412
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-38.3M
EBITDA	$-37.4M
EPS	$-0.45
F Score	3
FCF	$-18.8M
FCF EV Yield	-36.88x
FCF Per Share	$-0.19
Financing CF	40,300,000
Fiscal Year End	December
Founded	2,012
Investing CF	-7,030,000
Ipr	-91.22
Iprfo	-91.43
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-26
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	1.32
Ma150ch	-26.63%
Ma20	0.92
Ma20ch	5.47%
Net CF	14,556,000
Next Earnings Date	2026-05-22
Open	0.97
Optionable	Yes
Position In Range	54.83
Post Close	0.97
Postmarket Change Percent	0.97
Postmarket Price	$0.97
Ppne	5,054,000
Pre Close	0.93
Price Date	2026-05-08
Ptbv Ratio	2.92
Relative Volume	0.57x
Revenue	1,633,000x
SBC By Revenue	722.47x
Share Based Comp	11,798,000
Tr6m	-52.2%
Us State	California
Volume	402,291
Z Score	-2.41

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RANI pay a dividend?

Capital-return profile for this ticker.

Performance

RANI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RANI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+20.0%

Float: +64.5% of shares outstanding

Insider ownership

+3.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RANI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.5

Neutral momentum band

Price vs 200-day MA

-13.6%

50/200-day relationship not available

Beta (5Y)

0.76

Less volatile than the market

Sharpe ratio

0.74

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RANI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RANI stock rating?

Rani Therapeutics Holdings, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RANI analysis?

The full report lives at /stocks/RANI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RANI?

The latest report frames RANI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RANI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.